The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 15 - 2024 |
doi: 10.3389/fphar.2024.1461571
This article is part of the Research Topic Clinical Pharmacist Service Promotes the Improvement of Medical Quality Volume II View all 20 articles
Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China
Provisionally accepted- 1 Department of Pharmacy, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Gulin, China
- 2 Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Department of Oncology, Guilin, China
- 3 Department Electrophysiology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Gulin, China
- 4 Department of Oncology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Gulin, China
Purpose: The efficacy of tislelizumab plus chemotherapy in improving progression-free survival (PFS) and overall survival (OS) in unresectable gastric or gastroesophageal junction cancer (GC/GEJC) has recently been emphasized. This study compared the cost-effectiveness of tislelizumab plus chemotherapy versus placebo plus chemotherapy for the United States (US) and Chinese populations. Methods: Using data from the RATIONALE-305 phase 3 trial, a Markov model was developed to analyze quality-adjusted life years (QALYs), incremental cost-effectiveness ratios (ICERs), incremental net health benefits (INHBs), and incremental net monetary benefits (INMBs). The health state utilities and direct medical costs were obtained from the relevant literature and local cost databases. The model uncertainty was evaluated using sensitivity analyses.
Keywords: Cost-Effectiveness, Unresectable gastric cancer, unresectable gastroesophageal junction cancer, tislelizumab, Markov model
Received: 08 Jul 2024; Accepted: 06 Nov 2024.
Copyright: © 2024 Lang, Ai, Zhang, Jiang, He and Ouyang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wenwang Lang, Department of Pharmacy, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Gulin, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.